All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML
During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to Eliana Ruggiero, IRCCS Ospedale San Raffaele, Milan, IT. We asked, How can CRISPR be used for adoptive T-cell therapy in AML?
How can CRISPR be used for adoptive T-cell therapy in AML?
Ruggiero outlines the concept of adoptive T-cell therapy in AML. She discusses how CRISPR/Cas9 technology has demonstrated promising results in this area, in particular by limiting graft-versus-host disease and transplant-related toxicities.
Does disease burden affect outcome in de novo versus secondary AML?
During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to Claudia Núñez-Torrón, Hospital Universitario Ramón y Cajal,...
Allo-HSCT in patients with therapy-related AML or MDS
Therapy-related myeloid neoplasm (t-MN) is a secondary malignancy that can occur after being exposed to chemotherapy. 70% of t-MN cases appear 5–7 years after being treated with an alkylating...
Subscribe to get the best content related to AML delivered to your inbox